Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DprE2 is an essential enzyme in the biosynthetic pathway of mycobacterial cell wall components, specifically involved in the synthesis of decaprenylphosphoryl-D-arabinose (DPA). DPA serves as a lipid-linked arabinose donor required for constructing key cell wall polysaccharides such as arabinogalactan and lipoarabinomannan, which are crucial for the integrity and viability of Mycobacterium tuberculosis (Mtb). DprE2 forms a heteromeric membrane-bound epimerase complex with another enzyme, DprE1, and catalyzes the reduction step in the epimerization of decaprenylphosphoryl-D-2-keto-ribose (DPX) to DPA, utilizing NADH or NADPH as cofactors. Clinically relevant anti-tubercular drugs such as delamanid and pretomanid target this enzyme complex.
Inhibition of decaprenylphosphoryl-D-arabinose (DPA) synthesis, leading to defective cell wall biogenesis
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Decaprenylphosphoryl-D-ribose 2'-epimerase subunit E2.